ABSTRACT
Sympathetic innervation of the heart plays an important role in the pathophysiology of diseases, especially congestive heart failure and arrhythmias. Iodine-123 metaiodobenzylguanidine (I-123 MIBG) scintigraphy allows for early detection of problems by imaging at the neurotransmitter level before cardiac structural changes occur. In this way, it is possible to correctly manage the diagnosis and treatment processes of the patients. The main purpose of this guide is to ensure the national standardization of cardiac I-123 MIBG scintigraphy applications. In addition, it is intended to guide nuclear medicine doctors in the proper execution of indications, imaging and clinical processes, evaluation and reporting stages.
References
1
Hasan W. Autonomic cardiac innervation: development and adult plasticity. Organogenesis 2013;9:176-193.
2
Agostini D, Verberne HJ, Burchert W, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008;35:535-546.
3
Wakabayashi T, Nakata T, Hashimoto A, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001;42:1757-1767.
4
Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 2010;55:2769-2777.
5
Travin MI, Matsunari I, Thomas GS, Nakajima K, Yoshinaga K. How do we establish cardiac sympathetic nervous system imaging with 123I-mIBG in clinical practice? Perspectives and lessons from Japan and the US. J Nucl Cardiol 2019;26:1434-1451.
6
Al Badarin FJ, Wimmer AP, Kennedy KF, Jacobson AF, Bateman TM. The utility of ADMIRE-HF risk score in predicting serious arrhythmic events in heart failure patients: incremental prognostic benefit of cardiac 123I-mIBG scintigraphy. J Nucl Cardiol 2014;21:756-762.
7
Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardio 2016;23:606-639.
8
Merlet P, Piot O, Dubois-Randé JL, Loisance D, Castaigne A, Syrota A. Clinical use of metaiodobenzylguanidine imaging in cardiology. Q J Nucl Med 1995;39(Suppl 1):29-39.
9
Nagahara D, Nakata T, Hashimoto A, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzyl guanidine activity together with plasma natriuretic peptide concentration or left ventricularvfunction. J Nucl Med 2008;49:225-233.
10
Nakajima K, Nakata T. Cardiac 123I-MIBG Imaging for Clinical Decision Making: 22-Year Experience in Japan. J Nucl Med 2015;56(Suppl 4):11-19.
11
Nakajima K, Scholte AJHA, Nakata T, et al. Cardiac sympathetic nervous system imaging withv (123)I-meta-iodobenzylguanidine: Perspectives from Japan and Europe. J Nucl Cardiol 2017;24:952-960.
12
Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981;22:129-132.
13
Akturan S, Gümüş B, Özer Ö, et al. TÜİK Verilerine Göre Türkiye’de 2009 ve 2016 Yılları Arasındaki Ölüm Oranları ve Nedenleri. Konuralp Medical Journal/Konuralp Tip Dergisi 2019;11.
14
Asghar O, Arumugam P, Armstrong I, Ray S, Schmitt M, Malik RA. Iodine-123 metaiodobenzylguanidine scintigraphy for the assessment of cardiac sympathetic innervation and the relationship with cardiac autonomic function in healthy adults using standardized methods. Nucl Med Commun 2017;38:44-50.
15
Bellevre D, Manrique A, Legallois D, et al. First determination of the heart-to-mediastinum ratio using cardiac dual isotope (¹²³I-MIBG/⁹⁹mTc-tetrofosmin) CZT imaging in patients with heart failure: the ADRECARD study. Eur J Nucl Med Mol Imaging 2015;42:1912-1919.
16
Bombardieri E, Giammarile F, Aktolun C, et al. European Association for Nuclear Medicine. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:2436-2446.
17
Carrió I, Cowie MR, Yamazaki J, Udelson J, Camici PG. Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging 2010;3:92-100.
18
Carrió I, Flotats A. Cardiac sympathetic imaging with mIBG: a tool for better assessment of the diabetic heart. Eur J Nucl Med Mol Imaging 2010;37:1696-1697.
19
Dimitriu-Leen AC, Scholte AJ, Jacobson AF. 123I-MIBG SPECT for Evaluation of Patients with Heart Failure. J Nucl Med 2015;56(Suppl 4):25-30.
20
Dos Santos MJ, da Rocha ET, Verberne HJ, et al. Assessment of late anthracycline-induced cardiotoxicity by (123)I-mIBG cardiac scintigraphy in patients treated during childhood and adolescence. J Nucl Cardiol 2017;24:256-264.
21
Hachamovitch R, Nutter B, Menon V, Cerqueira MD. Predicting Risk Versus Predicting Potential Survival Benefit Using 123I-mIBG Imaging in Patients With Systolic Dysfunction Eligible for Implantable Cardiac Defibrillator Implantation: Analysis of Data From the Prospective ADMIRE-HF Study. Circ Cardiovasc Imaging 2015;8:003110.
22
Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol 2009;16:113-121.
23
Jacobson AF, Senior R, Cerqueira MD, et al. ADMIRE-HF Investigators. Myocardial iodine-123vmeta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (Adreiew Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-2221.
24
Kasama S, Toyama T, Sumino H, et al. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure andvreduced left ventricular ejection fraction. J Nucl Med 2008;49:907-914.
25
Kawai T, Yamada T, Tamaki S, et al. Usefulness of cardiac meta-iodobenzylguanidine imaging to identify patients with chronic heart failure and left ventricular ejection fraction <35% at low risk for sudden cardiac death. Am J Cardiol 2015;115:1549-1554.
26
Marino VSP, Dumont SM, Mota LDG, Braga DS, Freitas SS, Moreira MDCV. Sympathetic Dysautonomia in Heart Failure by 123I-MIBG: comparison between Chagasic, non-Chagasic and heart transplant patients. Arq Bras Cardiol 2018;111:182-190.
27
Marshall A, Cheetham A, George RS, Mason M, Kelion AD. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts ventricular arrhythmia in heart failure patients receiving an implantable cardioverter-defibrillator for primaryvprevention. Heart 2012;98:1359-1365.
28
Nakata T, Hashimoto A, Sugawara H. Cardiac metaiodobenzylguanidine imaging and heart failure. Curr Heart Fail Rep 2013;10:359-364.
29
Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multicenter cohort studiesvof (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 2013;6:772-784.
30
Narula J, Gerson M, Thomas GS, Cerqueira MD, Jacobson AF. ¹²³I-MIBG Imaging for Prediction of Mortality and Potentially Fatal Events in Heart Failure: ThevADMIRE-HFX Study. J Nucl Med 2015;56:1011-1018.
31
Rocha ET, Alves WEFM, Verschure DO, Verberne HJ. The use of Cardiac 123I-mIBG Scintigraphy in Clinical Practice: The Necessity to Standardize! Int J Cardiovasc Sci 2017;6:533-541.
32
Sciammarella MG, Gerson M, Buxton AE, et al. ASNC/SNMMI Model Coverage Policy: Myocardial sympathetic innervation imaging: Iodine-123 meta-iodobenzylguanidine ((123)I-mIBG). J Nucl Cardiol 2015;22:804-811.
33
Trägårdh E, Hesse B, Knuuti J, et al. Reporting nuclear cardiology: a joint position paper by the European Association of Nuclear Medicine (EANM) and the European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc Imaging 2015;16:272-279.
34
Shah AM, Bourgoun M, Narula J, Jacobson AF, Solomon SD. Influence of ejection fraction on the prognostic value of sympathetic innervation imaging withviodine-123 MIBG in heart failure. JACC Cardiovasc Imaging 2012;5:1139-1146.
35
Özcan Z, Gökçora N, Alan N, et al. Çocuklarda MIBG Sintigrafisi Kılavuzu. Turk J Nucl Med 2001:139-142.
36
Değer M, Demir M, İnce M, et al. Kalite Kontrol, Enstrümantasyon ve Radyasyon Güvenli¤i Komitesi Yönergesi. Turk J Nucl Med 2004; 13:118-139.